Reported 0 shares, down 956,945 (100.0%) from the prior quarter.
Reported value -100.0%; share count -100.0% vs. the prior quarter.
Reported position value by quarter
Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.
| Date | Holding Value |
|---|---|
| 2021-09-30 | 656000 |
| 2021-12-31 | 374000 |
| 2022-03-31 | 388000 |
| 2022-06-30 | 1367000 |
| 2022-09-30 | 763000 |
| 2022-12-31 | 1712206 |
| 2023-03-31 | 8653562 |
| 2023-06-30 | 9019506 |
| 2023-09-30 | 7566393 |
| 2023-12-31 | 22603041 |
| 2024-03-31 | 0 |
Quarterly position history
How this manager's reported quarter-end position changed over time.
| Quarter | Activity | Shares | Change | % of reported 13F | Reported value | Filed | Source filing |
|---|---|---|---|---|---|---|---|
| Q1 2024 | Reduced | 0 | -956,945 (-100.0%) | 0 | $0 | 2024-05-15 | |
| Q4 2023 | Added | 956,945 | +449,474 (88.6%) | < 0.01% | $22,603,041 | 2024-02-13 | |
| Q3 2023 | Reduced | 507,471 | -316,228 (-38.4%) | < 0.01% | $7,566,393 | 2023-11-15 | |
| Q2 2023 | Reduced | 823,699 | -168,682 (-17.0%) | < 0.01% | $9,019,506 | 2023-08-14 | |
| Q1 2023 | Added | 992,381 | +719,302 (263.4%) | < 0.01% | $8,653,562 | 2023-05-15 | |
| Q4 2022 | Added | 273,079 | +55,377 (25.4%) | < 0.01% | $1,712,206 | 2023-02-14 | |
| Q3 2022 | Reduced | 217,702 | -245,749 (-53.0%) | < 0.01% | $763,000 | 2022-11-14 | |
| Q2 2022 | Added | 463,451 | +338,932 (272.2%) | < 0.01% | $1,367,000 | 2022-08-15 | |
| Q1 2022 | Added | 124,519 | +13,720 (12.4%) | < 0.01% | $388,000 | 2022-05-13 | |
| Q4 2021 | Reduced | 110,799 | -69,069 (-38.4%) | < 0.01% | $374,000 | 2022-02-14 | |
| Q3 2021 | Reduced | 179,868 | -326,971 (-64.5%) | < 0.01% | $656,000 | 2021-11-15 | |
|
Five years are shown. A free account unlocks the complete reported history.
Unlock full history
|
|||||||
Who else reported the position
200 managers reported CYMABAY THERAPEUTICS INC for Q1 2024.
| Manager | Activity | Shares | Change | % of reported 13F | Reported value | Tenure |
|---|---|---|---|---|---|---|
| IFP Advisors Inc | Unchanged | 650 | 0 | < 0.01% | $21,077 | 19 qtrs |
| Legato Capital Management LLC | Reduced | 0 | -40,393 | 0 | $0 | 3 qtrs |
| VANGUARD GROUP INC | Reduced | 0 | -6,306,149 | 0 | $0 | 39 qtrs |
| Novo Holdings A S | Reduced | 0 | -900,000 | 0 | $0 | 4 qtrs |
| J Goldman & Co LP | Reduced | 0 | -165,937 | 0 | $0 | 3 qtrs |
| ALGERT GLOBAL LLC | Reduced | 0 | -84,883 | 0 | $0 | 16 qtrs |
| Entropy Technologies LP | Reduced | 0 | -27,116 | 0 | $0 | 2 qtrs |
| JANUS HENDERSON GROUP PLC | Reduced | 0 | -6,103,797 | 0 | $0 | 6 qtrs |
| BIT Capital GmbH | Reduced | 0 | -8,206 | 0 | $0 | 3 qtrs |
| Truvestments Capital LLC | Reduced | 0 | -1,364 | 0 | $0 | 13 qtrs |
Filing details and methodology As reported
- Report period
- March 31, 2024
- Filed
- May 15, 2024
- Filing type
- 13F-HR
- Position type
- COM
Voting authority reported
No voting-authority amounts were reported for this position. Voting authority is not required for reported call options.
Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.